Identification and characterization of the human ARD1-NATH protein acetyltransferase complex.

Department of Molecular Biology, University of Bergen, N-5020 Bergen, Norway.
Biochemical Journal (Impact Factor: 4.78). 04/2005; 386(Pt 3):433-43. DOI: 10.1042/BJ20041071
Source: PubMed

ABSTRACT Protein acetyltransferases and deacetylases have been implicated in oncogenesis, apoptosis and cell cycle regulation. Most of the protein acetyltransferases described acetylate epsilon-amino groups of lysine residues within proteins. Mouse ARD1 (homologue of yeast Ard1p, where Ard1p stands for arrest defective 1 protein) is the only known protein acetyltransferase catalysing acetylation of proteins at both alpha-(N-terminus) and epsilon-amino groups. Yeast Ard1p interacts with Nat1p (N-acetyltransferase 1 protein) to form a functional NAT (N-acetyltransferase). We now describe the human homologue of Nat1p, NATH (NAT human), as the partner of the hARD1 (human ARD1) protein. Included in the characterization of the NATH and hARD1 proteins is the following: (i) endogenous NATH and hARD1 proteins are expressed in human epithelial, glioma and promyelocytic cell lines; (ii) NATH and hARD1 form a stable complex, as investigated by reciprocal immunoprecipitations followed by MS analysis; (iii) NATH-hARD1 complex expresses N-terminal acetylation activity; (iv) NATH and hARD1 interact with ribosomal subunits, indicating a co-translational acetyltransferase function; (v) NATH is localized in the cytoplasm, whereas hARD1 localizes both to the cytoplasm and nucleus; (vi) hARD1 partially co-localizes in nuclear spots with the transcription factor HIF-1alpha (hypoxia-inducible factor 1alpha), a known epsilon-amino substrate of ARD1; (vii) NATH and hARD1 are cleaved during apoptosis, resulting in a decreased NAT activity. This study identifies the human homologues of the yeast Ard1p and Nat1p proteins and presents new aspects of the NATH and hARD1 proteins relative to their yeast homologues.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The X-linked lethal Ogden syndrome was the first reported human genetic disorder associated with a mutation in an N-terminal acetyltransferase (NAT) gene. The affected males harbour a Ser37Pro mutation in the gene encoding hNaa10, the catalytic subunit of NatA, the major human NAT involved in the co-translational acetylation of proteins. Structural models and molecular dynamics simulations of the human NatA and its Ser37Pro mutant highlight differences in regions involved in catalysis and at the interface between hNaa10 and the auxiliary subunit hNaa15. Biochemical data further demonstrate a reduced catalytic capacity and an impaired interaction between hNaa10 Ser37Pro and hNaa15 as well as hNaa50 (NatE), another interactor of the NatA complex. N-terminal acetylome analyses revealed a decreased acetylation of a subset of NatA and NatE substrates in Ogden syndrome cells, supporting the genetic findings and our hypothesis regarding reduced Nt-acetylation of a subset of NatA/NatE-type substrates as one etiology for Ogden Syndrome. Furthermore, Ogden syndrome fibroblasts display abnormal cell migration and proliferation capacity, possibly linked to a perturbed Retinoblastoma pathway. N-terminal acetylation clearly plays a role in Ogden syndrome, thus revealing the in vivo importance of N-terminal acetylation in human physiology and disease. © The Author 2014. Published by Oxford University Press.
    Human Molecular Genetics 03/2014; 24(7). DOI:10.1093/hmg/ddu611 · 6.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: NPMs correspond to the first modifications which any protein may undergo.•NPMs involve the N-terminal methionine excision pathway, N-α-acetylation and N-myristoylation.•NPM enzymes can be classified into several groups with specific features.•N-α-acetyltransferases and N-myristoyltransferases share a common GNAT fold.•Interaction with ribosome has been shown for several NPM enzymes.
    Biochimie 11/2014; DOI:10.1016/j.biochi.2014.11.008 · 3.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: ARD1 is present in various species and has several variants derived from alternative splicing of mRNA. Previously, we reported differential biological functions and cellular distributions of mouse ARD1 (mARD1) variants. However, in comparison to mARD1 variants, human ARD1 (hARD1) variants have been rarely studied. In this study, we characterized a hARD1 variant, hARD1131 and investigated its cellular activities. hARD1131 mRNA was isolated from HeLa cells and sequenced. Sequence alignment revealed that, compared to hARD1235, the most common form of hARD1, the mRNA sequence encoding hARD1131 possesses an altered reading frame due to a 46-bp deletion. Thus, hARD1131 and hARD1235 differ in their C-terminal regions with a partially deleted acetyltransferase domain at the C-terminus of hARD1131. Moreover, hARD1131 and hARD1235 showed different subcellular localizations and biological functions. hARD1131 was mostly localized in the cell nucleus, whereas hARD1235 was primarily localized in the cytoplasm. In addition, hARD1235 stimulated cell prolifer-ation by upregulation of cyclin D1, however hARD1131 had no influence on cyclin D1 expression and cell growth. Because hARD1235 enhances cell proliferation by its autoacetylation activity, we examined the autoacetylation activity of hARD1131 and observed that this function was absent in hARD1131. These results suggest that human ARD1 variants have different effects on cell prolifer-ation, which may result from distinct subcellular localizations and autoacetylation activities.
    International Journal of Oncology 11/2014; 46(2). DOI:10.3892/ijo.2014.2770 · 2.77 Impact Factor


Available from